Filing Flows

Filing Flows › Companies › BioNexus Gene Lab › Cash flow

BioNexus Gene Lab cash flow, quarter by quarter

Latest: Q2 2026 · from the cash-flow statements filed with the SEC

Free cash flow−$423K in Q2 2026 · −$854K over twelve months

Operating cash flow−$422K
Capital spending−$250
Free cash flow−$423K
Cash conversion cycle1001 days

Analysis

In Q2 2026, BioNexus Gene Lab generated −$422K of operating cash flow and spent $250 on capital projects, leaving free cash flow of −$423K. That is $337K more than in Q2 2025 (−$759K).

Over the twelve months to Jun 30, 2026, operating cash flow was −$847K; the largest uses were operating cash flow ($847K), capital spending ($7K); besides operations, cash came from other investing ($1.4M), other financing ($265K); the cash balance rose by $855K.

Operating cash flow was −$422K against net income of −$286K. The largest differences: depreciation & amortization +$28K, deferred taxes −$0.

Its cash conversion cycle was 1001 days (receivables 57 + inventory 951 − payables 7).

Free cash flow

BioNexus Gene Lab: free cash flow by quarterBioNexus Gene Lab: free cash flow by quarter−$1.8MQ3 2024$215KQ4 2024−$833KQ1 2025−$759KQ2 2025−$1.2MQ3 2025$960KQ4 2025−$148KQ1 2026−$423KQ2 2026
Operating cash flow less capital spending.
BioNexus Gene Lab: operating cash flow against capital spendingBioNexus Gene Lab: operating cash flow against capital spendingOperating cash flowCapital spending−$1.6M$199KQ3 2024$219K$4KQ4 2024−$824K$9KQ1 2025−$738K$21KQ2 2025−$1.2M$5KQ3 2025$961K$1KQ4 2025−$148K$325Q1 2026−$422K$250Q2 2026
Latest (Q2 2026): Operating cash flow −$422K, Capital spending $250.

Capital allocation, year by year

BioNexus Gene Lab: where the cash came from (up) and went (down), by fiscal yearBioNexus Gene Lab: where the cash came from (up) and went (down), by fiscal yearOperating cash flowNet borrowingShares issuedCapital spendingFY2021: Operating cash flow $9KFY2021: Capital spending −$3K$9KFY2021FY2022: Operating cash flow $552K$552KFY2022FY2023: Operating cash flow −$1.8MFY2023: Net borrowing $1.4MFY2023: Capital spending −$149K$1.4MFY2023FY2024: Operating cash flow −$2.1MFY2024: Net borrowing $83KFY2024: Shares issued $80KFY2024: Capital spending −$227K$163KFY2024FY2025: Operating cash flow −$1.8MFY2025: Net borrowing $32KFY2025: Shares issued $267KFY2025: Capital spending −$37K$300KFY2025
Over these 5 years operating cash flow totalled −$5.2M; the largest uses were operating cash flow ($5.8M) and capital spending ($417K). Cash-flow statements as filed.

Cash runway and the debt wall

Cash & investments$1.2M
Debtnone
Net cash$1.2M
Cash runway17 months

BioNexus Gene Lab is burning cash: its operations consume cash, a free cash flow of −$854K a year at the current rate against $1.2M of cash and investments: a runway of about 17 months before any new financing.

Where the cash came from and went

BioNexus Gene Lab: sources (+) and uses (−) of cash, Q2 2026BioNexus Gene Lab: sources (+) and uses (−) of cash, Q2 2026Operating cash flow−$422KOther investing$416KOther financing$19KExchange rates−$13KCash drawn (+) / kept (−)$6KNet borrowing (+) / repaid (−)−$6KCapital spending−$250
BioNexus Gene Lab: sources (+) and uses (−) of cash, TTM to Q2 2026BioNexus Gene Lab: sources (+) and uses (−) of cash, TTM to Q2 2026Other investing$1.4MCash drawn (+) / kept (−)−$855KOperating cash flow−$847KOther financing$265KNet borrowing (+) / repaid (−)$109KExchange rates−$64KCapital spending−$7K

From profit to cash

BioNexus Gene Lab: net income to operating cash flow, Q2 2026BioNexus Gene Lab: net income to operating cash flow, Q2 2026Net income−$286KDepreciation & amortization$28KOperating cash flow−$422K
Non-cash charges are added back; money tied up in receivables or inventory is subtracted.
QuarterReceivable daysInventory daysPayable daysCash conversion cycle
Q2 20265795171001
Q1 20261154255993704
Q4 202519315918334
Q3 202561473375
Q1 202559646756
Q4 202451585356
Q3 202442484051

Every quarter

QuarterOperating cash flowCapital spendingNet borrowing (+) / repaid (−)Shares issuedCash drawn (+) / kept (−)Free cash flow
Q2 2026−$422K−$250−$6K—$6K−$423K
Q1 2026−$148K−$325$81K—$88K−$148K
Q4 2025$961K−$1K−$497—−$1.1M$960K
Q3 2025−$1.2M−$5K$34K—$180K−$1.2M
Q2 2025−$738K−$21K−$1K—$552K−$759K
Q1 2025−$824K−$9K$15K—$798K−$833K
Q4 2024$219K−$4K−$1K$1K−$222K$215K
Q3 2024−$1.6M−$199K−$197K$2K$1.3M−$1.8M

BioNexus Gene Lab: income statement and cash flow

BioNexus Gene Lab, Q2 2026: revenue $76K (-97% year over year), operating margin -370.8%. The chart follows the revenue to costs, profit and cash.

BioNexus Gene Lab: every quarter, Q/Q and Y/Y → Open in the app

Read automatically from the company’s XBRL cash-flow statements; quarterly figures for the fourth quarter are the year less the first three. Errors are possible. Not investment advice.